We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

Drugless Treatment for Hypertension

By HospiMedica staff writers
Posted on 03 Jun 2002
Utilizing patented sensor technology, a new device translates a patient's individual breathing patterns into customized musical tones that guide the patient to lengthen the expiratory phase and thus slow breathing to fewer than 10 breaths per minute. More...
After the exercise, breathing returns to normal, but the beneficial effects on blood pressure accumulate. Use of the device for fifteen minutes per day produced an average reduction in blood pressure of 12 mmHg systolic and six mmHg diastolic in just six weeks of treatment. The reduction was greater for older people and for people with higher initial blood pressure. Results were independent of both gender and medication status.

The device, called Resperate, is the product of InterCure, Ltd. (Lod, Israel). The company states that the benefits of the device have been demonstrated in seven clinical trials involving more than 300 patients. The device has been cleared by the US Food and Drug Administration (FDA) for the adjunctive treatment of hypertension.

"The Resperate device provides physicians and patients with a new, much-needed option to further lower blood pressure without adding medications to a patient`s existing routine,” said Dr. Cristina Giannattasio, who conducted one of InterCure`s clinical studies at the University of Milan-Bicocca, Italy. "The majority of the patients enrolled in this study were already taking multiple medications, while still exhibiting uncontrolled blood pressure. With Resperate, we were able to lower their blood pressure significantly with no side effects whatsoever.”




Related Links:
InterCure, Ltd.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Desk Aneroid Sphyg
Diagnostix 750D+
New
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.